Poseida therapeutics hosts cell therapy r&d day highlighting its innovative clinical and preclinical pipeline

Emerging leadership in allogeneic car-t for hematologic malignancies demonstrated by recent p-bcma-allo1 phase 1 data and new preclinical findings for p-cd19cd20-allo1 and p-cd70-allo1 latest preclinical data on p-bcmacd19-allo1 demonstrates its potential as a next-generation allogeneic tscm-rich car-t for both autoimmune diseases and oncology advancing innovative strategies to overcome the unique challenges of applying car-t to solid tumors virtual r&d day featuring partner astellas pharma and poseida's leadership and scientific teams to be held today at 10:00am et / 7:00am pt san diego , nov. 14, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated t stem cell memory cells (tscm)-rich allogeneic car-t therapies in oncology and autoimmune diseases during a virtual r&d day to be held today at 10:00am et / 7:00am pt. "we believe poseida is well positioned to be a cell therapy leader based on the unique capabilities of our proprietary non-viral technology platform and our allogeneic tscm-rich car-t approach," said kristin yarema, ph.d.
CAR Ratings Summary
CAR Quant Ranking